PubMed=2300817; DOI=10.1126/science.2300817
Jeffrey M. Trent, Eric John Stanbridge, Heyoung L. McBride, Eckart U. Meese, Graham Casey, Diana E. Araujo, Colette M. Witkowski, Raymond B. Nagle;
Tumorigenicity in human melanoma cell lines controlled by introduction of human chromosome 6.
Science 247:568-571(1990)

PubMed=10952317; DOI=10.1038/35020115
Michael Bittner, Paul S. Meltzer, Yi-Dong Chen, Yuan Jiang, Elisabeth A. Seftor, Mary J.C. Hendrix, Michael D. Radmacher, Richard M. Simon, Zohar Yakhini, Amir Ben-Dor, Nick Sampas ...Show all 28 authors... , Edward Russell Dougherty, Ena Wang, Francesco M. Marincola, Gerald C. Gooden, John Lueders, Arthur Glatfelter, Pamela M. Pollock, John D. Carpten, Elizabeth M. Gillanders, Darryl Leja, Kathleen Dietrich, Christian Beaudry, Michael E. Berens, David Samuel Alberts, Vernon K. Sondak, Nicholas K. Hayward, Jeffrey M. Trent; Show fewer authors
Molecular classification of cutaneous malignant melanoma by gene expression profiling.
Nature 406:536-540(2000)

PubMed=23039341; DOI=10.1186/1476-4598-11-75; PMCID=PMC3554420
Sara A. Byron, David C. Loch, Candice L. Wellens, Andreas Wortmann, Jia-Yi Wu, John Wang, Kenichi Nomoto, Pamela M. Pollock;
Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status.
Mol. Cancer 11:75.1-75.15(2012)

PubMed=24879157; DOI=10.4161/auto.28594; PMCID=PMC4091172
Megan L. Goodall, Tong Wang, Katie R. Martin, Matthew G. Kortus, Audra L. Kauffman, Jeffrey M. Trent, Stephen Gately, Jeffrey P. MacKeigan;
Development of potent autophagy inhibitors that sensitize oncogenic BRAF V600E mutant melanoma tumor cells to vemurafenib.
Autophagy 10:1120-1136(2014)